4D Medical (ASX:4DX) share price rises on maiden half-year results

The 4DMedical (ASX:4DX) share price is trading higher today after the company announced its half-yearly results. We take a closer look.

4DMedical Ltd (ASX: 4DX) shares are on the rise today after the company released its half-year results for the period ending 31 December 2020 (1H21). At the time of writing, the 4DMedical share price is trading 2.06% higher at $1.735. At one point during intraday trading, 4DMedical shares rallied by as much as 7% before retreating to their current levels.

Let's take a look at how the medical imaging company has been performing.

Young doctor raising arms in air with hands in fists celebrating a new development.

Image source: Getty Images

What's driving the 4DMedical share price higher?

The 4DMedical share price is trending higher today after the company posted its first-ever 1H report since listing late last year.

In today's release, the company outlined its progress since its successful initial public offering (IPO) that raised $55.79 million. During the period, 4DMedical received Australian TGA approval for its lung imaging software-as-a-service (SaaS) platform. This is a critical milestone for the company to be able to generate meaningful revenue moving forward and was achieved six months ahead of schedule.

In other news boosting the 4DMedical share price, the company also announced it has secured its first United States research program to advance its lung imaging technology in collaboration with the University of Miami.

Regarding the company's financials, 4D Medical ended the half-year period with $43.04 million cash at bank. The company's revenue from ordinary activities during the half-year was derived from maintenance services relating to its scanners.

This revenue declined 86% from the prior corresponding period (pcp), which included $1.10 million in sales of preclinical hardware. Other income increased 29% to $1.08 million, comprised of tax incentives, grant income, and JobKeeper subsidies.

The company's net loss for the period rose strongly to $13.14 million, up 145% compared to a loss of $5.37 million in the pcp. 4DMedical stated that "the operating result was consistent with management's plans."

Management comments

4D Medical founder and CEO Andreas Fouras addressed the results saying:

The first half of FY21 was an extremely busy period for 4DMedical in which we achieved some major operational milestones, such as the company listing on the Australian Securities Exchange (ASX), as well as making significant progress towards commercialisation in both the U.S. and Australia. I am extremely proud of our team's achievements, particularly whilst faced with COVID-19 which continues to create a level of uncertainty and reduced decision-making capacity, particularly in the U.S.

It has not been a good start to the year for the 4DMedical share price. Year to date, the company's share have fallen by nearly 29%, faring far worse than the All Ordinaries Index (ASX: XAO), which has delivered a 2.3% gain so far this year.

Based on the current 4DMedical share price, the company commands a market capitalisation of around $300 million.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »